Patents by Inventor Ronnie Charles Mease

Ronnie Charles Mease has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20220088229
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Application
    Filed: April 22, 2021
    Publication date: March 24, 2022
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20200282083
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Application
    Filed: November 5, 2019
    Publication date: September 10, 2020
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • PSMA-binding agents and uses thereof
    Patent number: 10500292
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: December 10, 2019
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20180236110
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 23, 2018
    Inventors: MARTIN G. POMPER, RONNIE CHARLES MEASE, YING CHEN
  • PSMA-binding agents and uses thereof
    Patent number: 9861713
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: January 9, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20160114060
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Application
    Filed: January 4, 2016
    Publication date: April 28, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. POMPER, Ronnie Charles MEASE, Ying CHEN
  • PSMA-binding agents and uses thereof
    Patent number: 9226981
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 5, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie Charles Mease, Ying Chen
  • PSMA-targeting compounds and uses thereof
    Patent number: 9056841
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 16, 2015
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin Pomper, Ronnie Charles Mease, Ray Sangeeta, Ying Chen
  • PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20140369931
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 18, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE CHARLES MEASE, YING CHEN
  • PSMA-binding agents and uses thereof
    Patent number: 8778305
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: July 15, 2014
    Assignee: The Johns Hopkins University
    Inventors: Martin Pomper, Ronnie Charles Mease, Ying Chen
  • PSMA-TARGETING COMPOUNDS AND USES THEREOF
    Publication number: 20120009121
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Application
    Filed: March 19, 2010
    Publication date: January 12, 2012
    Applicant: The Johns Hopkins University
    Inventors: Martin Pomper, Ronnie Charles Mease, Ray Sangeeta, Ying Chen
  • PSMA-BINDING AGENTS AND USES THEREOF
    Publication number: 20110142760
    Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
    Type: Application
    Filed: July 31, 2009
    Publication date: June 16, 2011
    Applicant: The Johns Hopkins University
    Inventors: Martin Pomper, Ronnie Charles Mease, Ying Chen